Polaryx Therapeutics, Inc. (NASDAQ:PLYX) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Polaryx Therapeutics, Inc. (NASDAQ:PLYX) has earned a consensus rating of “Moderate Buy” from the five ratings firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, two have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $7.67.

Several brokerages have issued reports on PLYX. Zacks Research raised shares of Polaryx Therapeutics to a “hold” rating in a report on Friday, July 10th. Weiss Ratings reaffirmed a “sell (e)” rating on shares of Polaryx Therapeutics in a report on Monday, September 28th. Wall Street Zen upgraded shares of Polaryx Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 12th. HC Wainwright began coverage on shares of Polaryx Therapeutics in a research note on Thursday, July 9th. They issued a “buy” rating and a $7.00 target price on the stock. Finally, Raymond James Financial began coverage on Polaryx Therapeutics in a research report on Thursday, August 13th. They issued a “strong-buy” rating and a $6.00 price target on the stock.

Polaryx Therapeutics Trading Up 1.4%

Shares of NASDAQ:PLYX opened at $2.10 on Friday. Polaryx Therapeutics has a 1-year low of $1.85 and a 1-year high of $48.91. The firm has a market capitalization of $104.69 million and a PE ratio of -26.25. The business’s 50 day moving average is $2.11 and its 200-day moving average is $3.22.

Polaryx Therapeutics (NASDAQ:PLYX) last issued its earnings results on Thursday, August 13th. The company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.02. On average, sell-side analysts predict that Polaryx Therapeutics will post -0.22 EPS for the current year.

Polaryx Therapeutics Company Profile

We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.